• +1-646-491-9876
    • +91-20-67278686

    Search

    Myocardial Infarction - Pipeline Review, H1 2017

    Myocardial Infarction - Pipeline Review, H1 2017

    • Report Code ID: RW0001709449
    • Category Pharmaceuticals
    • No. of Pages 307
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Myocardial Infarction - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

    Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness) .

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 14, 9, 37, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 20 and 7 molecules, respectively.

    Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 5
    Myocardial Infarction - Overview 6
    Myocardial Infarction - Therapeutics Development 7
    Myocardial Infarction - Therapeutics Assessment 22
    Myocardial Infarction - Companies Involved in Therapeutics Development 34
    Myocardial Infarction - Drug Profiles 60
    Myocardial Infarction - Dormant Projects 275
    Myocardial Infarction - Discontinued Products 281
    Myocardial Infarction - Product Development Milestones 282
    Appendix 295

    List of Tables

    Number of Products under Development for Myocardial Infarction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
    Myocardial Infarction - Pipeline by AstraZeneca Plc, H1 2017
    Myocardial Infarction - Pipeline by Athersys Inc, H1 2017
    Myocardial Infarction - Pipeline by Bayer AG, H1 2017
    Myocardial Infarction - Pipeline by Bharat Biotech International Ltd, H1 2017
    Myocardial Infarction - Pipeline by BioCardia Inc, H1 2017
    Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
    Myocardial Infarction - Pipeline by Capricor Therapeutics Inc, H1 2017
    Myocardial Infarction - Pipeline by CellProthera, H1 2017
    Myocardial Infarction - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017
    Myocardial Infarction - Pipeline by Compugen Ltd, H1 2017
    Myocardial Infarction - Pipeline by Cynata Therapeutics Limited, H1 2017
    Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
    Myocardial Infarction - Pipeline by FibroGen Inc, H1 2017
    Myocardial Infarction - Pipeline by Hemostemix Ltd, H1 2017
    Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2017
    Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H1 2017
    Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H1 2017
    Myocardial Infarction - Pipeline by Inotrem SA, H1 2017
    Myocardial Infarction - Pipeline by Juventas Therapeutics Inc, H1 2017
    Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2017
    Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
    Myocardial Infarction - Pipeline by LG Chem, Ltd., H1 2017
    Myocardial Infarction - Pipeline by Medestea Research & Production SpA, H1 2017
    Myocardial Infarction - Pipeline by Mesoblast Ltd, H1 2017
    Myocardial Infarction - Pipeline by Moderna Therapeutics Inc, H1 2017
    Myocardial Infarction - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
    Myocardial Infarction - Pipeline by New World Laboratories Inc, H1 2017
    Myocardial Infarction - Pipeline by Novartis AG, H1 2017
    Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H1 2017
    Myocardial Infarction - Pipeline by Omeros Corp, H1 2017
    Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H1 2017
    Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Myocardial Infarction - Pipeline by Pharmahungary Group, H1 2017
    Myocardial Infarction - Pipeline by Primary Peptides Inc, H1 2017
    Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H1 2017
    Myocardial Infarction - Pipeline by Recardio GmbH, H1 2017
    Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
    Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
    Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H1 2017
    Myocardial Infarction - Pipeline by Serodus ASA, H1 2017
    Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2017
    Myocardial Infarction - Pipeline by Stemedica Cell Technologies Inc, H1 2017
    Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
    Myocardial Infarction - Pipeline by Targazyme Inc, H1 2017
    Myocardial Infarction - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
    Myocardial Infarction - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2017
    Myocardial Infarction - Pipeline by TiGenix NV, H1 2017
    Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2017
    Myocardial Infarction - Pipeline by XBiotech Inc, H1 2017
    Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H1 2017
    Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Myocardial Infarction - Dormant Projects, H1 2017
    Myocardial Infarction - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Myocardial Infarction - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Myocardial Infarction - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Myocardial Infarction - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Myocardial Infarction - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Myocardial Infarction - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Myocardial Infarction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Amarantus Bioscience Holdings Inc
    AstraZeneca Plc
    Athersys Inc
    Bayer AG
    Bharat Biotech International Ltd
    BioCardia Inc
    Biscayne Pharmaceuticals Inc
    Capricor Therapeutics Inc
    CellProthera
    Chrysalis BioTherapeutics Inc
    Compugen Ltd
    Cynata Therapeutics Limited
    Diffusion Pharmaceuticals Inc
    FibroGen Inc
    Hemostemix Ltd
    Human Stem Cells Institute
    HUYA Bioscience International LLC
    InCarda Therapeutics Inc
    Inotrem SA
    Juventas Therapeutics Inc
    Laboratoires Pierre Fabre SA
    Lee's Pharmaceutical Holdings Ltd
    LG Chem, Ltd.
    Medestea Research & Production SpA
    Mesoblast Ltd
    Moderna Therapeutics Inc
    Navya Biologicals Pvt Ltd
    New World Laboratories Inc
    Novartis AG
    NuvOx Pharma LLC
    Omeros Corp
    Opsona Therapeutics Ltd
    Otsuka Holdings Co Ltd
    Pharmahungary Group
    Primary Peptides Inc
    Quark Pharmaceuticals Inc
    Recardio GmbH
    RegeneRx Biopharmaceuticals Inc
    Reliance Life Sciences Pvt Ltd
    Rubicon Biotechnology Inc
    Serodus ASA
    Silver Creek Pharmaceuticals Inc
    Stemedica Cell Technologies Inc
    TaiGen Biotechnology Co Ltd
    Targazyme Inc
    Tasly Pharmaceutical Group Co Ltd
    The International Biotechnology Center (IBC) Generium
    TiGenix NV
    Vicore Pharma AB
    XBiotech Inc
    Yuyu Pharma Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//myocardial-infarction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//myocardial-infarction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//myocardial-infarction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments